Clinical Trial Detail

NCT ID NCT03217747
Title Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prostate cancer

Advanced Solid Tumor

Therapies

Avelumab + PF-04518600 + Utomilumab

Avelumab + Utomilumab

Avelumab + PF-04518600

Age Groups: senior adult

No variant requirements are available.